logo

Centre of Evidence of Dermatology Best practice guidelines

Guidelines classic scabies: in children < 15kg, pregnant or breastfeeding women Updated on january 2024

Responsibility

The information provided by this website comes from sources deemed reliable. However, the French Dermatology Society recommends that the user ensure the validity of this information. Some may prove to be erroneous or be subject to typos or display errors.

The use of this data is under the sole responsibility of the user. The French Dermatology Society cannot be blamed for a misinterpretation of the data provided by the site, or in the event of erroneous information. This decision tree and all the contents of this site have been developed in the context of updated data from science according to the HAS methodology, expert opinions and reviewers of the various documents and in the context of the French healthcare system.

Click on a profile and its situation to read the recommendation.

Don’t miss the terms of application of the treatments, the associated measures or the more specific cases.

Grouped cases Associated measures Administration methods Algorithms Out of licence Woman breastfeeding* Woman pregnant* Child < 15kg > 24 months Infant < 15kg 2 - 24 months Infant < 2 months D0 + D8~14 D0 + D8~14 D0 + D8~14 D0 + D8~14 D0 + D8~14 1 st LINE 2 nd LINE ** * ivermectin: infectious disease advice required if stay in tropical zone exposes to risk of lioasis ** after confirming failure and analysing the conditions leading to failure Breastfeeding measures Case of profuse scabies (and/or hyperkeratotic scabies) Repeat in case of failure Ivermectin preferred if compliance in doubt, poor skin condition or grouped cases guideline Topical treatments or oral ivermectin* depending on skin / niple condition guideline Repeat in case of failure Ivermectin for any term preferred if compliance in doubt, poor skin condition or grouped cases guideline Topical treatments or oral ivermectin* depending on skin condition in 2 nd and 3 rd trimester (only 2 nd intention in 1 st trimester) guideline Repeat in case of failure Ivermectin preferred if compliance in doubt, poor skin condition or grouped cases guideline Topical treatmentsor oral ivermectin* Ivermectin preferred if compliance in doubt, poor skin condition or grouped cases guideline Topical treatmentsor oral ivermectin* Ivermectin preferred if compliance in doubt, poor skin condition or grouped cases guideline Topical treatments Permethrin preferable <1 yearor damaged skinor facial involvement(periorbital and perioral region) guideline Repeat in case of failure guideline Permethrin 5% cream Discuss hospitalization depending on context guideline

Practice with our clinical vignettes

Specific information

Treatments

Other Informations

Diagnosis

Epidemiology

  • Was this article helpful to you?

  • Your opinion counts!

    This notice will not be published on this site, but only sent to the publication management. Your email will only be used to reply to you if we deem it necessary. No response will be sent to any request for medical advice via this form.

➜ Table of contents

Centre of Evidence of Dermatology Centre of Evidence of Dermatology logo
Work
10 cité Malesherbes
75009Paris
Île-de-France
FRANCE
Work +33.1 43 27 01 56
Fax +33.1 43 27 01 86
centredepreuvesdermato@sfdermato.org